1. Identification of global inhibitors of cellular glycosylation.
- Author
-
Sørensen, Daniel, Büll, Christian, Madsen, Thomas, Lira-Navarrete, Erandi, Clausen, Thomas, Clark, Alex, Garretson, Aaron, Karlsson, Richard, Pijnenborg, Johan, Yin, Xin, Miller, Rebecca, Chanda, Sumit, Boltje, Thomas, Schjoldager, Katrine, Vakhrushev, Sergey, Halim, Adnan, Esko, Jeffrey, Carlin, Aaron, Hurtado-Guerrero, Ramon, Weigert, Roberto, Clausen, Henrik, and Narimatsu, Yoshiki
- Subjects
Animals ,Glycosylation ,SARS-CoV-2 ,COVID-19 ,Glycoproteins ,Polysaccharides - Abstract
Small molecule inhibitors of glycosylation enzymes are valuable tools for dissecting glycan functions and potential drug candidates. Screening for inhibitors of glycosyltransferases are mainly performed by in vitro enzyme assays with difficulties moving candidates to cells and animals. Here, we circumvent this by employing a cell-based screening assay using glycoengineered cells expressing tailored reporter glycoproteins. We focused on GalNAc-type O-glycosylation and selected the GalNAc-T11 isoenzyme that selectively glycosylates endocytic low-density lipoprotein receptor (LDLR)-related proteins as targets. Our screen of a limited small molecule compound library did not identify selective inhibitors of GalNAc-T11, however, we identify two compounds that broadly inhibited Golgi-localized glycosylation processes. These compounds mediate the reversible fragmentation of the Golgi system without affecting secretion. We demonstrate how these inhibitors can be used to manipulate glycosylation in cells to induce expression of truncated O-glycans and augment binding of cancer-specific Tn-glycoprotein antibodies and to inhibit expression of heparan sulfate and binding and infection of SARS-CoV-2.
- Published
- 2023